Community/Retail

Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.

Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.

At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.

Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.

Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.

A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.

Eric Lawitz, MD, explains how pharmacists can discuss liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.

A lipidologist outlines how PREVENT, coronary calcium scoring, and restored LDL-C targets guide personalized lipid therapy and where pharmacists fit in.

As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.

The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.

A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.

From red meat to 'big and fluffy' LDL, a lipid expert unpacks fat and cholesterol misconceptions that persist among patients and clinicians.

Pharmacists play a large role in mavacamten care, screening for interacting drugs that can raise exposure and may require dose adjustment or withholding.

As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.

Validating patient concerns and then reframing them around stroke prevention can help pharmacists counsel patients who worry that statins harm memory.

Michael Mina, MD, PhD, discusses phase 3 LIBERTY study data showing that the monoclonal antibody VYD2311, alone or combined with an mRNA COVID-19 vaccine, was associated with fewer adverse events than vaccination alone.

In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.

Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.

Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.

Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.

Alexander Turchin, MD, MS, recommends shared decision-making, time-limited lifestyle trials, and gentle persistence to move patients toward statins.

A lipidologist traces patient fears to 2012 FDA label language and reviews observational and randomized data showing no cognitive harm from statins.

As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.

Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.

In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.